secwatch.observer — SEC 8-K summary
======================================

Issuer:     SeaStar Medical Holding Corp (ICU)
CIK:        0001831868
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0000950170-25-071390
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SeaStar Medical Q1 net revenue rises to $293K; net loss narrows to $3.8M
------------------------------------------------------------------------

- Net product revenue ~$293K, a four-fold increase from Q4 2024's $68K.
- Net loss of $3.8M ($0.44/share) vs $12.7M ($4.73/share) a year ago.
- NEUTRALIZE-AKI trial 50% enrolled; interim analysis by DSMB expected Q3 2025.
- Two new Breakthrough Device Designations for SCD therapy in cardiac surgery (adult & ped).
- Cash $5.3M as of March 31, 2025 vs $1.8M Dec 31, 2024; $6M offering closed Jan 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831868/000095017025071390/0000950170-25-071390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831868/000095017025071390/icu-20250514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-071390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer